Caveolin-1 is a member of a subset of intracellular proteins that regulate endothelial nitric oxide synthase (eNOS) activity. In caveolae, caveolin-1 inhibits eNOS activity via a direct interaction with the enzyme. Previous work has indicated that both eNOS and caveolin-1 are also localized at the perinuclear Golgi complex. Whether caveolin-1 is involved in eNOS regulation in this cell compartment is unknown. Here we studied the localization of eNOS and caveolin-1 in the perinuclear region of primary bovine aortic endothelial cells. By immunofluorescence microscopy we show that both eNOS and caveolin-1 co-localize with Golgi markers. On treatment of the cells with the microtubule-depolymerizing drug nocodazole, the Golgi complex is scattered and caveolin-1 is found in vesicles at the periphery of the cell, while eNOS is localized at large structures near the nucleus. The nocodazole-induced redistribution of eNOS is similar to that of cis -, medial-, and trans -Golgi markers, while the caveolin-1 redistribution resembles that of sec22, a marker for the intermediate compartment. The localization of eNOS and caveolin-1 at distinct perinuclear compartments that behave differently in the presence of nocodazole indicates that eNOS activity is not regulated by caveolin-1 in the Golgi complex.
T he enzyme endothelial nitric oxide synthase (eNOS) generates nitric oxide (NO), which is essential for vascular function (Loscalzo and Welch 1995; Cooke and Dzau 1997) . It is involved in vessel dilatation, inhibition of platelet and leukocyte adhesion, and inhibition of proliferation and migration of vascular smooth muscle cells. In relation to these NO-dependent processes, an impaired eNOS function has been implicated in several major cardiovascular diseases, such as hypertension (Taddei et al. 1998 ) and hypercholesterolemia (Casino et al. 1993) . Therefore, eNOS needs to be tightly regulated (for reviews on eNOS regulation see Govers and Rabelink 2001) . Proteins that activate eNOS are calmodulin (Sessa et al. 1992) , Hsp90 (Garcia-Cardena et al. 1998) , Akt kinase (Dimmeler et al. 1999) , and dy-namin-2 (Cao et al. 2000) . The negative regulators known thus far are caveolin-1 and NOSIP (Dedio et al. 2001) . Caveolin-1 inhibits eNOS that is present in caveolae via a direct interaction between a specific amino acid sequence within caveolin-1, called the scaffolding domain, and a motif in the oxygenase domain of eNOS that is rich in aromatic amino acid residues (Garcia Cardena et al. 1997 ). The caveolin-1 scaffolding domain is also involved in the inhibition of many other signaling molecules, including Ras , c-Src tyrosine kinase , G-protein ␣ -subunits (Li et al. 1995) , and epidermal growth factor receptor ). In addition, an interaction between caveolin-1 and the reductase domain of eNOS has also been demonstrated (Ghosh et al. 1998 ). Although eNOS is kept inactive by caveolin-1 in caveolae, its specific localization at this cell organelle is required for activation. This is concluded from studies in which the palmitoylation sites of eNOS had been removed, which resulted in the disappearance of eNOS from caveolae and loss of its activity, although it remained membrane-associated (Liu et al. 1996) . On stimulation of the endothelial cell with agonists such as bradykinin, thrombin, or VEGF, the interaction between eNOS and caveolin-1 is lost, while eNOS associates with calmodulin, resulting in the generation of NO (Feron et al. 1998) .
At present it is not clear whether eNOS that is localized at the Golgi complex is active or might be activated by specific stimuli. If Golgi-resident eNOS can be activated, it may also be associated with caveolin-1. Caveolin-1 is reported to be present at the Golgi complex and is believed to recycle between this organelle and the caveolae at the plasma membrane (Conrad et al. 1995) . In addition, caveolin-1 may also be present at the ER (Smart et al. 1996; Pol et al. 2001) . The hypothesis that eNOS is already associated with caveolin-1 at the Golgi has been postulated (Garcia-Cardena et al. 1996a) . If this were the case, eNOS and caveolin-1 need to be localized at the same subcompartment of the Golgi complex.
In this study we used the microtubule-depolymerizing agent nocodazole to determine whether eNOS and caveolin-1 are localized at the same subcompartment of the Golgi. By depolymerizing the microtubules, nocodazole induces fragmentation of the Golgi complex (Cole et al. 1996) . Nocodazole treatment is a wellestablished method to localize proteins to distinct Golgi subcompartments (Chavrier et al. 1990; Rojo et al. 1997; Yang and Storrie 1998; Zhang et al. 1999 ).
Here we show that treatment of bovine aortic endothelial cells (BAECs) with nocodazole causes segregation of eNOS-and caveolin-1-containing vesicular structures, indicating that these proteins are not present at the same subcompartment of the Golgi and that caveolin-1 has no regulatory role in eNOS function at this compartment.
Materials and Methods

Materials
BAECs were purchased from Clonetics (San Diego, CA). Normal goat serum and secondary fluorescent antibodies were obtained from Jackson Immunochemicals (West Grove, PA). Monoclonal anti-eNOS antibody (immunofluorescence) was purchased from BioMol (Plymouth Meeting, PA) and monoclonal anti-eNOS (immuno-EM), anti-caveolin-1 (#C37120), and anti-GM130 from Transduction Laboratories (San Diego, CA). Polyclonal anti-caveolin-1 (#C13630), anti-myc, and anti-mannosidase II antibodies were obtained from Transduction Laboratories (San Diego, CA), Upstate Biotechnologies (Lake Placid, NY), and K.W. Moremen (University of Georgia; Athens, GA), respectively. Polyclonal anti-GOS-28 antibody was raised in rabbits using the His6-tagged cytoplasmic portion of GOS-28 (His6-GOS-28-⌬ TM) as immunogen (Gerez et al. 2000) . Anti-sec22 antibody was a generous gift from Richard Scheller (Stanford University School of Medicine; Stan-ford, CA). Myc-␣ -2,6-sialyltransferase cDNA in SMH4 vector was kindly provided by Sean Munro (MRC, Cambridge, UK). Nocodazole was obtained from Sigma (St Louis, MO).
Cell Culture
Primary BAECs were cultured according to the supplier's instructions. BAECs were cultured in EGM BulletKit medium (Clonetics), split 1:6 on reaching confluence, and used between passages 3 to 7. For immunofluorescence, cells were grown on glass coverslips in 24-well dishes. The different passage number of the cells used for the experiments did not affect the localization of any of the studied proteins. All experiments were performed at 37C. Because of a better morphology, cells were used at a subconfluent stage. Cell confluence did not affect the Golgi localization of any of the proteins described in this study.
For transfection of BAECs with the eukaryotic expression vector pcDNA3.1 (Invitrogen; Carlsbad, CA) containing myc-␣ -2,6-sialyltransferase cDNA (cloned in HindIII/XbaI sites), cells were incubated with DNA-Lipofectamine complexes according to the supplier's instructions (Life Technologies; Rockville, MD).
Immunofluorescence Microscopy
BAECs were immunostained by indirect fluorescent labeling. Cells were incubated with 20 M nocodazole for the time periods indicated. To study the reversibility of the nocodazole-induced Golgi scattering, cell cultures were incubated with nocodazole for 60 min, washed once with preconditioned medium without nocodazole, and incubated with medium for the indicated periods of time.
After nocodazole incubation, cells were fixed with 3% paraformaldehyde, permeabilized, blocked with normal goat serum, incubated with primary antibodies for 60 min, washed three times with PBS, incubated with secondary antibodies (goat anti-rabbit-FITC and goat anti-mouse-Texas Red) for 30 min, washed three times with PBS, and embedded in Mowiol. Confocal laser scanning microscopy was performed using a Leica TCS 4D system. FITC and Texas Red label were scanned sequentially and overlaid using Adobe Photoshop software. Control cells that were labeled with the primary or secondary antibody only showed no fluorescence (not shown).
Immunoelectron Microscopy
BAECs were fixed by mixing the culture medium 1:1 with double-strength fixative (4% paraformaldehyde, 2% acrolein in 0.1 M sodium phosphate buffer, pH 7.4) at ambient temperature. After 4 min the mixture was replaced by single-strength fixative (2% paraformaldehyde, 1% acrolein in phosphate buffer) and fixation proceeded for 2.5 hr at room temperature. Then cells were scraped and processed for ultracryotomy and immuno-EM as described (Raposo et al. 1997) . Briefly, ‫ف‬ 60-nm-thick cryosections were thawed and immunolabeled for eNOS by incubating them with a monoclonal anti-eNOS antibody, rabbit anti-mouse IgG, and protein A-gold successively. Sections were then stained with uranyl acetate and dried in methylcellulose. Control cryosections that were labeled with secondary antibody and protein A-gold only showed no labeling (not shown).
Results
Immunofluorescence observations revealed a typical perinuclear localization for eNOS ( Figure 1A) . By immuno-EM these eNOS-positive areas were recognized as the Golgi apparatus, in which eNOS appeared to be distributed in a rather diffuse fashion over all recognizable Golgi elements, including the cisternae and vesicular/tubular membranes in their surroundings ( Figure 1C ). Anti-caveolin-1 antibody gave identical perinuclear labeling patterns by immunofluorescence as eNOS ( Figure 1B ). However, immuno-EM was not successful for caveolin-1 localization, which is probably due to differences in the processing of the cells. Therefore, nocodazole in combination with immunofluorescence was used to study the localization of eNOS and caveolin-1 in detail and to see whether these proteins are actually present at the same subcompartment of the Golgi. BAECs were treated with nocodazole for various periods of time, after which the cells were fixed, labeled with monoclonal antibodies against eNOS and caveolin-1, and analyzed by confocal immunofluorescence microscopy ( Figure 2 ). An antibody against the Golgi SNARE [soluble N -ethylmaleimide-sensitive factor (NSF) attachment protein receptor] GOS-28 (Nagahama et al. 1996) was used as a reference because the cells could not be double labeled for eNOS and caveolin-1 at the same time. From 0 to 30 min of nocodazole treatment there was only a minor change in eNOS and GOS-28 staining. A more dramatic redistribution of eNOS and GOS-28 was seen after 1 and 3 hr of nocodazole treatment. After 3 hr of nocodazole, both proteins could be detected in vesicular structures throughout the cell. At all time points, eNOS co-localized with GOS-28. In contrast, caveolin-1 started to appear in GOS-28-negative structures within 5 min of nocodazole treatment. At 30 min, there was still a considerable amount of colocalization between caveolin-1 and GOS-28, but after 60 min of nocodazole treatment there was hardly any overlap left. Remarkably, caveolin-1 was redistributed into vesicular structures throughout the cell that were predominantly located at the other site of the nucleus compared to GOS-28. The absence of colocalization was transient, and co-localization of caveolin-1 and GOS-28 returned after 3 hr of nocodazole treatment. At that time, both caveolin-1 and GOS-28 co-localized in structures that were distributed evenly throughout the cell, which resembled the eNOS distribution after 3 hr of nocodazole. Therefore, nocodazole induces a rapid, transient redistribution of caveolin-1 into eNOS-and GOS-28-negative vesicular structures.
The reversibility of the drug treatment was also studied. BAECs were incubated for 1 hr with nocodazole, washed, and incubated for various time periods in the absence of nocodazole (Figure 3 ). eNOS and GOS-28 returned to their original perinuclear Golgilike distribution between 15 and 60 min after drug removal. Most of the caveolin-1 co-localized with GOS-28 (and therefore also with eNOS) within 10 minutes after the nocodazole was removed from the cells. This co-localization was complete after 15 min. This clearly demonstrates that on nocodazole removal, the caveolin-1-positive vesicles quickly redistribute from the cell periphery towards the large nocodazoleinduced eNOS-and GOS-28-containing Golgi fragments before these structures regain their original perinuclear morphology.
To define the Golgi subcompartments in which eNOS and caveolin-1 are localized, BAECs were incubated for 1 hr with nocodazole and labeled with monoclonal antibodies directed against eNOS, caveolin-1, and Golgi matrix protein GM130 (Nakamura et al. 1995) in combination with polyclonal antibodies directed against caveolin-1, mannosidase II (Moremen and Robbins 1991), myc-tag (for the detection of transfected myc-tagged sialyltransferase) (Taatjes et al. 1988) , and Golgi SNAREs sec22 (Hay et al. 1998) , and GOS-28 ( Figure 4 ). In the absence of nocodazole, both eNOS and caveolin-1 co-localized with the Golgi protein GOS-28 in the perinuclear Golgi complex, which was also positive for all of the other studied proteins (Figure 4 , left panels). In immunofluorescence microscopy, the monoclonal anti-caveolin-1 antibody recognized only the caveolin-1 present in the Golgi and did not react with cell surface caveolin-1, as has been described for other anti-caveolin-1 antibodies directed against the COOH-terminus of caveolin-1 (Luetterforst et al. 1999) . To ascertain the validity of the monoclonal anti-caveolin-1 antibody, a double labeling with a polyclonal anti-caveolin-1 antibody was performed. The polyclonal antibody predominantly stained caveolae at the plasma membrane. In addition, the antibody immunolabeled Golgi and Golgi fragments that were also labeled by the monoclonal anticaveolin-1 antibody ( Figure 4C) . As for the monoclonal antibody, the polyclonal anti-caveolin-1 antibody did not label the nocodazole-induced Golgi fragments that were positive for eNOS. In nocodazole-treated cells, eNOS co-localized with the cis -Golgi marker GM130 (since GM130 co-localized with GOS-28; Figure 4D) , with the cis /medial-Golgi marker mannosidase II ( Figure 4E ) and with the trans -Golgi/TGN marker tST (transfected sialyltransferase; Figure 4F ). Caveolin-1 did not co-localize with these Golgi markers (not shown).
Because our data indicated that caveolin-1 was not present in Golgi stacks or TGN, BAECs were double labeled with antibodies against caveolin-1 and sec22 ( Figure 4G ). Sec22 is a marker for the intermediate compartment (IC). The sec22 antibody labeled the Golgi region as well as peripheral vesicular structures, most likely representing vesicular tubular clusters (VTCs) near the Golgi and peripheral VTCs adjacent to ER exit sites, respectively (Hay et al. 1998; Chao et al. 1999) . In nocodazole-treated BAECs, caveolin-1positive vesicles were also labeled with anti-sec22 antibody. Strikingly, in these cells a minor part of the sec22-positive structures was not labeled by the anticaveolin-1 antibody. This may account for the presence of a relatively small amount of sec22 in the cis -Golgi (Hay et al. 1998) . Because in non-treated cells caveolin-1 does not co-localize with sec22 at peripheral VTCs, this indicates that caveolin-1 is localized at Golgi-adjacent VTCs of the intermediate compartment. eNOS co-localized with sec22 in the absence but not in the presence of nocodazole (not shown), which indicates that eNOS is not present at the intermediate compartment. Furthermore, this demonstrates that the identical perinuclear immunolabeling of proteins (in cells not treated with nocodazole), as judged by immunofluorescence techniques, does not indicate that both proteins actually co-localize nor does it imply the presence of both proteins at the Golgi. 
Discussion
The data presented here demonstrate that eNOS and caveolin-1 are localized at distinct perinuclear cell compartments that behave differently when exposed to the Golgi-disrupting drug nocodazole. A 1-hr incubation of BAECs with nocodazole results in a shift in the cellular distribution of eNOS and caveolin-1 from a dense perinuclear Golgi-like structure into a vesicular staining pattern, with virtually no overlap between eNOS and caveolin-1. The caveolin-1-positive vesicles, in contrast to the structures containing eNOS, are highly dynamic. Their formation is initiated after 5 min of drug treatment and within 10 min after nocodazole removal most of these vesicles can no longer be distinguished from eNOS-containing structures. Unfortunately, it was impossible to confirm these data by immuno-EM because in these cells none of the caveolin-1 antibodies that were tested labeled caveolin-1 in or near the Golgi complex using immuno-EM techniques.
The Golgi markers GOS-28, GM130, mannosidase II, ␣ -2,6-sialyltransferase, and the IC marker sec22 were studied to determine the perinuclear (sub)compartments where eNOS and caveolin-1 are localized. The Golgi v-SNARE GOS-28 is localized predominantly at vesicles at the terminal rims of the Golgi stacks, where it is involved in intra-Golgi transport (Nagahama et al. 1996) . GM130 is a Golgi matrix protein and plays a role in maintaining the cis -Golgi structure and in mitotic fragmentation of the Golgi complex (Nakamura et al. 1995; Lowe et al. 1998) . Mannosidase II and ␣ -2,6-sialyltransferase are enzymes involved in carbohydrate modification and are localized at the cis /medial-Golgi and trans -Golgi/TGN, respectively (Taatjes et al. 1988; Moremen and Robbins 1991) . The SNARE sec22 is predominantly localized at VTCs of the intermediate compartment and to a small extent at the cis -Golgi (Hay et al. 1998; Zhang et al. 1999) . In contrast, the localization of caveolin-1 within the Golgi is less clear. Caveolin-1 was initially thought to be present in the TGN (Dupree et al. 1993 ), but later investigations documented its localization to the cis -Golgi (Luetterforst et al. 1999) . We now found that, in nocodazole-treated cells, caveolin-1 and markers of the cis -and trans -Golgi distribute to distinct locations. Possibly the distribution of caveolin-1 within the Golgi complex is subject to cell typespecific regulation. Yang and Storrie (1998) have demonstrated that, in nocodazole-treated cells, trans -Golgi/TGN markers rapidly redistribute to scattered cytoplasmic patches and that only on prolonged treatment do these structures become positive for proteins of the other Golgi stacks. However, we have not seen any preferential scattering of trans -Golgi/TGN proteins in BAECs that have been treated with nocodazole. col-leagues (1997,1999) have shown that nocodazole can be used in localization studies to differentiate between Golgi and Golgi-adjacent VTCs of the intermediate compartment. In agreement, our data show that in BAECs nocodazole induces a rapid redistribution of the IC marker sec22 to peripheral structures that become positive for Golgi stack markers after prolonged nocodazole treatment. Because caveolin-1 redistributes with kinetics that are similar to those of sec22 (data not shown), this indicates that caveolin-1 is localized at the IC. The co-localization of caveolin-1 and the IC marker sec22 during nocodazole treatment is in agreement with data from Conrad and colleagues (1995) . Furthermore, because sec22 but not caveolin-1 is also present in peripheral VTCs near ER exit sites, our data demonstrate that caveolin-1 is not distributed throughout the entire IC but is localized at Golgiadjacent VTCs only. eNOS maintains its co-localization with Golgi stack markers during nocodazole treatment, which indicates that eNOS is not present at the IC but at the Golgi. Furthermore, by immunoelectron microscopy we show that eNOS is present throughout the Golgi complex and is not concentrated at any particular part of the Golgi. The lack of colocalization of eNOS and caveolin-1 at the Golgi suggests that Golgi-resident eNOS is not regulated by caveolin-1.
The Golgi localization of eNOS is dependent on its first 35 amino acid residues (Liu et al. 1997) . Its presence at the Golgi is mediated by myristoylation at its amino-terminus (Gly-2), whereas eNOS palmitoylation (at Cys-15 and -26) is not required for eNOS localization at the Golgi but for targeting of eNOS to caveolae (Sessa et al. 1995; Garcia-Cardena et al. 1996b ). Because palmitoyl-deficient eNOS shows a marked decrease in NO-generating capacity in intact cells, although the activity of purified mutant eNOS is not impaired, the localization of eNOS at the Golgi complex is required but not sufficient for proper NO synthesis (Liu et al. 1996) . Therefore, it is unlikely that Golgi-localized eNOS produces significant amounts of NO. The lack of co-localization of eNOS and caveolin-1 within the Golgi apparatus suggests that within this compartment eNOS is kept inactive by another interacting protein. Other potential mechanisms that may be responsible for this include phosphorylation (Fleming et al. 2001 ) and the (local) absence of factors that are required for its enzymatic activity (e.g., calcium, l -arginine, and tetrahydrobiopterin). eNOS that is present in the Golgi complex does not represent a silent eNOS pool. Using kinetic fluorescence techniques on eNOS-GFP chimeric proteins in living cells, it was shown that eNOS is rapidly transported to and from the Golgi complex (Sowa et al. 1999 ). In addition, nocodazole treatment causes a 35% decrease in eNOS activity (data not shown), which might indicate that the localization of eNOS at the Golgi complex is important for its cellular regulation.
Previous studies have shown that in BAECs eNOS is activated by shear stress (Buga et al. 1991) , estradiol (Goetz et al. 1999) , and VEGF (He et al. 1999) . Because eNOS in the Golgi complex is not likely to be involved in the production of NO, eNOS will also be localized at caveolae at the cell surface. However, in our studies we were unable to detect much eNOS at the plasma membrane of BAECs using immunofluoresence techniques. This is most probably caused by a relatively low amount of eNOS at the plasma membrane compared to the Golgi complex where, in addition, the high density of membranes accentuates its presence. That BAECs do express eNOS at the plasma membrane is evident from other studies (Garcia-Cardena et al. 1996b; Kim et al. 1999) .
Our studies indicate that eNOS and its inhibitor caveolin-1 do not co-localize within the Golgi complex. Because Golgi-resident eNOS is probably not involved in NO production, this may imply the presence of other regulatory proteins in the Golgi complex that reduce eNOS activity. An important step in understanding the complex cellular regulation of eNOS will now be to reveal the mechanism by which eNOS activity is regulated in this cell compartment.
Figure 4
Nocodazole-induced redistribution of Golgi proteins. BAECs were incubated for 60 min in the absence (left panels) or presence (right panels) of 20 M nocodazole, fixed, and indirectly immunolabeled with the indicated antibodies. Red staining represents immunolabeling with antibodies against eNOS ( A,E,F ), caveolin-1 (MAb) ( B,C,G ) , and GM130 ( D ). Green staining represents GOS -28 ( A,B,D ) , caveolin-1 (PAb) ( C ), mannosidase II ( E ), transfected sialyltransferase (tST) ( F ), and sec22 ( G ). Third image in each panel shows an overlay of the images of the indicated antibodies. Arrowheads in second image of G (sec22) indicate peripheral VTCs near ER exit sites; arrowheads in sixth image of G (merge) indicate caveolin-1-negative sec22-positive structures, which presumably originate from the cis -Golgi. Bar ϭ 5 m.
